VISIT NUTRACEUTICALS WORLD at Booth 4872 TEST

Almac, THREAD to Integrate Technologies for Clinical Trials

07.28.21

Integrating technology platforms aims to provide sponsors and CROs with a full range of tools designed to reduce the risk of trial delays.

Almac Clinical Technologies, a member of the Almac Group, and THREAD, a technology and service provider enabling decentralized clinical trials (DCTs), entered a strategic partnership to integrate technologies to enable more efficient clinical trials that generate better outcomes.
 
By integrating their technology platforms, Almac and THREAD will provide sponsors and contract research organizations (CROs) with a full range of tools designed to reduce the risk of trial delays. Almac’s IXRS solution and services for randomization and clinical trial supply management will be available to THREAD customers and THREAD’s DCT solution will be available to Almac customers. The two companies will leverage single sign-on and application program interfaces (APIs) to integrate their technologies and automate DCT workflows across their respective platforms.
 
The integration aims to minimize duplicate data entry, particularly for research sites, provide sponsors with integrated reports on trial progress, and preserve automation to ensure operational efficiency.
 
“We’re thrilled to be working with THREAD, an acknowledged leader in DCT technology,” said George Tiger, vice president of Global Business Development, Almac Clinical Technologies. “As part of our growing Partnership and Alliance program, this specific partnership will enable us to offer an additional level of support to Almac clients as they seek to decentralize their clinical trials.”
 
“A common pain point for research sites is the abundance of technologies they have to independently maintain for each clinical trial,” said John Reites, chief executive officer of THREAD. “By integrating Almac within our comprehensive platform, sites and study teams will have a single DCT study experience. Almac is a longstanding global leader in clinical research, and we’re excited about this synergistic partnership.”